Julie Bines

Last updated

Julie Bines is a clinician and researcher working in Melbourne, Australia. Alongside being a professor and deputy head of the Department of Paediatrics at the University of Melbourne, [1] she is also a paediatric gastroenterologist at the Royal Children's Hospital Melbourne [2] and is the leader of the Enteric Diseases group at the Murdoch Children's Research Institute. [3] Bines is the joint head of the WHO Collaborative Centre for Child Health [4] and founding member of Women in Global Health Australia. [5]

Contents

“Think broadly, don’t be siloed within your own discipline; listen to what’s happening in the community.” Bines, in an interview with Engaging Women [6] .

Career and research

Bines attended Monash University, graduating with a Bachelor of Medicine, Bachelor of Surgery (MBBS) in 1982, later attaining her Doctorate of Medicine from the University of Melbourne in 1990. [7] She trained as a clinical and research fellow in Paediatric Gastroenterology and Nutrition at Massachusetts General hospital and Harvard Medical School, Boston (1988–91) and a postdoctoral fellow at the Massachusetts Institute of Technology (1989–91). [7] After travelling through Asia, Africa and Europe for 12 months during her residency at the Royal Children's Hospital, Bines became fixed on pediatrics with a focus on addressing the global disparity in healthcare. [1] Beyond her contributions to rotavirus research and vaccine development, Bines' recent research has expanded to investigate the impact of the COVID pandemic on women and children worldwide. [8]

Novel rotavirus vaccine development

Bines and her team developed a novel oral rotavirus vaccine (RV3-BB) as a global vaccine against infant rotavirus infection based on a naturally occurring and attenuated human strain of rotavirus originally isolated from healthy babies. [9] Rotavirus can be prevented, there are two available vaccines [10] , however vaccine cost makes it unaffordable for many developing countries. An estimated 1,205 children die from rotavirus disease each day, and 82% of these deaths occur in children in the poorest countries [11] . Bines and her team successfully developed an affordable rotavirus vaccine that is orally administered and accessible to newborns, who are particularly susceptible to the virus.

Clinical trials were carried out in Australia, New Zealand, Malawi and Indonesia, achieving 95% protection about severe rotavirus-associated gastroenteritis in the first year of life and up 75% protection in infants up to 18 months of age. [12] [13] Trial funding was provided by the National Health and Medical Research Council (NHMRC), Bill & Melinda Gates Foundation and PT BioFarma [14] . Providing an affordable vaccine that can be easily stored, delivered, and administered at birth is crucial, as mothers and babies are more likely to be with a healthcare provider at that time. Most notably, this vaccine has been developed to improve efficacy and availability in developing countries by optimizing the delivery time and developing manufacturing processes to reduce production costs. [15]

Outreach

Bines has been involved in outreach campaigns to dispel myths and misinformation about vaccines, [16] as well as appearing on national radio to talk about her work. [17]

Awards and honours

Selected publications

References

  1. 1 2 Cigognini B (2 December 2021). "Professor Julie Bines". Melbourne Medical School. Retrieved 7 April 2022.
  2. ↑ "Gastroenterology and Clinical Nutrition : The team". www.rch.org.au. Retrieved 7 April 2022.
  3. ↑ "Enteric Diseases - Murdoch Children's Research Institute". www.mcri.edu.au. Retrieved 7 April 2022.
  4. ↑ "WHOCC - WHO Collaborating Centres". apps.who.int. Retrieved 7 April 2022.
  5. ↑ "Steering Committee". Women in Global Health Australia. Retrieved 7 April 2022.
  6. ↑ Martine (6 August 2017). "The fight against Rotavirus". Engaging Women. Retrieved 19 February 2025.
  7. 1 2 "Professor Julie Bines | Murdoch Children's Research Institute". www.mcri.edu.au. Retrieved 7 April 2022.
  8. ↑ "GLHAM National COVID Briefing - The knock-on effect: how the pandemic is uniquely impacting the health of women and girls". Australian Global Health Alliance. Retrieved 7 April 2022.
  9. 1 2 At Thobari J, Damayanti W, Haposan JH, Nirwati H, Iskandar K, Fahmi J, et al. (July 2021). "Safety and immunogenicity of human neonatal RV3 rotavirus vaccine (Bio Farma) in adults, children, and neonates in Indonesia: Phase I Trial". Vaccine. 39 (33): 4651–4658. doi: 10.1016/j.vaccine.2021.06.071 . PMID   34244006. S2CID   235787849.
  10. ↑ CDC (12 December 2024). "Rotavirus Vaccination". Rotavirus. Retrieved 19 February 2025.
  11. ↑ Parashar, Umesh D.; Hummelman, Erik G.; Bresee, Joseph S.; Miller, Mark A.; Glass, Roger I. (May 2003). "Global Illness and Deaths Caused by Rotavirus Disease in Children". Emerging Infectious Diseases. 9 (5): 565–572. doi:10.3201/eid0905.020562. ISSN   1080-6040. PMC   2972763 . Archived from the original on 5 February 2025.
  12. 1 2 Bines JE, Danchin M, Jackson P, Handley A, Watts E, Lee KJ, et al. (December 2015). "Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial". The Lancet. Infectious Diseases. 15 (12): 1389–1397. doi:10.1016/S1473-3099(15)00227-3. PMID   26318715.
  13. ↑ Bines, Julie E.; At Thobari, Jarir; Satria, Cahya Dewi; Handley, Amanda; Watts, Emma; Cowley, Daniel; Nirwati, Hera; Ackland, James; Standish, Jane; Justice, Frances; Byars, Gabrielle; Lee, Katherine J.; Barnes, Graeme L.; Bachtiar, Novilia S.; Viska Icanervilia, Ajeng (22 February 2018). "Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth". New England Journal of Medicine. 378 (8): 719–730. doi:10.1056/NEJMoa1706804. ISSN   0028-4793. PMC   5774175 . Archived from the original on 2 February 2025.
  14. ↑ "New rotavirus vaccine could save lives". SBS News. Retrieved 19 February 2025.
  15. 1 2 Hamidi A, Hoeksema F, Velthof P, Lemckert A, Gillissen G, Luitjens A, et al. (April 2021). "Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine". Vaccine. 39 (15): 2048–2059. doi:10.1016/j.vaccine.2021.03.033. PMC   8062787 . PMID   33744044.
  16. ↑ Choahan N (2 October 2018). "The science of immunisation: Dispelling vaccination myths" . Retrieved 7 April 2022.
  17. ↑ "Rotavirus scientist among Eureka Prize finalists". ABC Radio National. 2 September 2021. Retrieved 7 April 2022.
  18. ↑ Vince C (2 September 2021). "Scientists pave the way for a brighter future in Research & Innovation category at 2021 Australian Museum Eureka Prizes". The Australian Museum. Retrieved 7 April 2022.
  19. ↑ "Current AGA Fellows". American Gastroenterological Association. Retrieved 7 April 2022.
  20. ↑ "Game changer through a new vaccine for Rotavirus". NHMRC. 24 May 2020. Retrieved 7 April 2022.
  21. ↑ Thomas S, Donato CM, Covea S, Ratu FT, Jenney AW, Reyburn R, et al. (March 2021). "Genotype Diversity before and after the Introduction of a Rotavirus Vaccine into the National Immunisation Program in Fiji". Pathogens. 10 (3): 358. doi: 10.3390/pathogens10030358 . PMC   8002601 . PMID   33802966.
  22. ↑ Danchin MH, Bines JE, Watts E, Cowley D, Pavlic D, Lee KJ, et al. (April 2020). "Rotavirus specific maternal antibodies and immune response to RV3-BB rotavirus vaccine in central java and yogyakarta, Indonesia". Vaccine. 38 (16): 3235–3242. doi:10.1016/j.vaccine.2020.02.087. PMID   32160948. S2CID   212677834.
  23. ↑ Tosif S, Neeland MR, Sutton P, Licciardi PV, Sarkar S, Selva KJ, et al. (November 2020). "Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19". Nature Communications. 11 (1): 5703. Bibcode:2020NatCo..11.5703T. doi:10.1038/s41467-020-19545-8. PMC   7658256 . PMID   33177504.
  24. ↑ Bines JE, Kirkwood CD (January 2015). "Conquering rotavirus: from discovery to global vaccine implementation". Journal of Paediatrics and Child Health. 51 (1): 34–39. doi:10.1111/jpc.12815. PMID   25586843. S2CID   5492363.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.